• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Baek Richard Jaihwan

    7/21/25 4:30:17 PM ET
    $LIMN
    Get the next $LIMN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Baek Richard JaiHwan

    (Last) (First) (Middle)
    6 CENTERPOINTE DR. #625

    (Street)
    LA PALMA CA 90623

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    Liminatus Pharma, Inc. [ LIMN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Richard Baek 07/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LIMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIMN
    SEC Filings

    View All

    SEC Form 10-K filed by Liminatus Pharma Inc.

    10-K - Liminatus Pharma, Inc. (0001971387) (Filer)

    3/31/26 5:28:24 PM ET
    $LIMN

    Liminatus Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

    3/4/26 4:15:50 PM ET
    $LIMN

    SEC Form SCHEDULE 13G filed by Liminatus Pharma Inc.

    SCHEDULE 13G - Liminatus Pharma, Inc. (0001971387) (Subject)

    2/20/26 4:15:43 PM ET
    $LIMN

    $LIMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

    CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies. IBA101 is engineered to target the CD47 "don't-eat-me" signal, a mechanism that enables tumor cells to evade innate immune surveillance. By enhancing macrophage-mediated tumor clearance and antigen presentation, IBA101 is designed to work alongside PD-1/PD-L1 checkpoint inhibitors, which remain the backbone of treatment across multiple solid tumor indications. The planned Phase 1 study is designed as a s

    3/17/26 8:08:00 AM ET
    $LIMN

    Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

    CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of  its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary

    2/17/26 8:44:00 AM ET
    $LIMN

    Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

    LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets. Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. sec

    10/30/25 10:04:29 AM ET
    $LIMN

    $LIMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Iris Acquisition Holdings Llc claimed ownership of 6,900,000 shares (SEC Form 3)

    3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

    8/15/25 2:50:20 PM ET
    $LIMN

    SEC Form 3 filed by new insider Lemons Ii Philip Wayne

    3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

    7/23/25 2:19:58 PM ET
    $LIMN

    SEC Form 3 filed by new insider Baek Richard Jaihwan

    3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

    7/21/25 4:30:17 PM ET
    $LIMN